Orca Bio vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Orca Bio is developing high-purity precision cell therapies using proprietary cell sorting technology to improve the safety and outcomes of bone marrow transplantation; raised $270M+; lead programs in AML, MDS, and other blood cancers;
About
Orca Bio is a Menlo Park, California-based biotechnology company founded in 2016 that is developing next-generation cell therapies for blood cancers and autoimmune diseases through a proprietary high-precision cell sorting and manufacturing platform. The company's core technology enables the production of precisely defined cell therapy products — specifically, highly purified stem cell grafts and engineered immune cell compositions for allogeneic (donor-to-patient) bone marrow transplantation. Unlike conventional bone marrow transplants, which transfer a heterogeneous mixture of cells that can attack the patient's body (graft-versus-host disease, or GVHD), Orca Bio's manufactured grafts are composed of precisely selected cell populations that retain the anti-cancer effect while dramatically reducing the cells responsible for GVHD.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.